A lawyer at a company regulated by the Food and Drug Administration has filed a lawsuit to prevent counsel’s personally identifiable information from being disclosed in the agency’s apparently damning inspection report scheduled for release this week.

The “reverse FOIA” case filed Tuesday in U.S. District Court for the District of Columbia raises more questions than it answers, however—including whether it is actually a clever tactic to limit disclosure of reputationally damaging information about the company.